ClinicalTrials.gg
RecruitingNCT04494945Updated Jul 14, 2026

Identifying and Caring for Individuals With Inherited Cancer Syndrome

An interventional study of Biospecimen Collection and Genetic Counseling in BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome, Breast Ductal Carcinoma In Situ and Hematopoietic and Lymphoid System Neoplasm, sponsored by OHSU Knight Cancer Institute. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by OHSU Knight Cancer Institute · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2020, registered Jul 2020).
  • Started Mar 2020; still recruiting 6 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27,500
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Hereditary Breast and Ovarian Cancer Syndrome · United States.

Planned enrollment
Largest of 23
27,500 · median 157
Started
2020
with 3 others
No phase
17 of 35
4 open now
Registered
26th of 35
by date

Among the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, this one has the largest planned enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2020, is one of 17 with no phase, and was the 26th registered.

Hereditary Breast and Ovarian Cancer Syndrome

62 studies on the registry are indexed under Hereditary Breast and Ovarian Cancer Syndrome; 13 are open to participants now.

Browse Hereditary Breast and Ovarian Cancer Syndrome studies →

Open to participants now

7 of the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Hereditary Breast and Ovarian Cancer Syndrome studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, or all of them as a file.
02

Study summary

This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testing to the general public. Researchers hope to learn the value of providing broad, public-wide testing for high risk cancer types (like hereditary breast and ovarian cancer or Lynch syndromes) instead of only testing people whose families are known to be high risk.

Read the detailed description

PRIMARY OBJECTIVE:

I. Evaluate the effectiveness and sustainability of heritable cancer syndrome testing in two proposed screening populations compared to current guidelines.

SECONDARY OBJECTIVES:

I. Measure adherence to current guidelines for screening and prophylactic intervention of Cohorts B and C compared to Cohort A to show non-inferiority.

II. Measure the efficiency of cascade testing (defined as the ratio of family members screened over total possible) for Cohorts B and C compared to Cohort A to show non-inferiority.

III. Determine the costs and effectiveness, specifically quality adjusted life years (QALYs) associated with genetic screening models based on Cohorts B and C to estimate incremental cost-effectiveness ratio (ICER) and show that the costs per QALY are below the acceptable cost effectiveness threshold.

OUTLINE:

Patients undergo collection of saliva samples for genetic testing. If genetic test is positive, patients receive genetic counseling. Patients also complete a survey about cancer prevention, screening, and treatment.

03

Conditions studied

  • BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
  • Breast Ductal Carcinoma In Situ
  • Hematopoietic and Lymphoid System Neoplasm
  • Hereditary Neoplastic Syndrome
  • Lynch Syndrome
  • Malignant Solid Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • ALL COHORTS: 18 years of age or older
  • Retrospective COHORT A: Per HIPAA waiver, Retrospective Cohort A will not actively consent
  • Retrospective COHORT A: Patients may or may not be diagnosed with cancer
  • Retrospective COHORT A: Patients have received genetic counseling in the past 5 years
  • Retrospective COHORT A: Patients have genetic variants that include BRCA1, BRCA2 and/or Lynch syndrome
  • COHORT A: Per Health Insurance Portability and Accountability Act (HIPAA) waiver, Cohort A returns survey as consent
  • COHORT A: Patients may or may not be diagnosed with cancer
  • COHORT A: Patients have received genetic counseling in the past 1 - 2 years
  • COHORT A: Patients have genetic variants that include BRCA1, BRCA2 and/or Lynch syndrome
  • COHORT A: INCLUSIVE of no contact list to exclude from Cohort B
  • COHORT B: Creation of secure Healthy Oregon Project (HOP) app account
  • COHORT B: Consent to this project, either hard or electronic signature
  • COHORT B: Consent to the HOP repository, either hard or electronic signature
  • COHORT B: Choosing to submit a deoxyribonucleic acid (DNA) sample
  • COHORT B: Patients diagnosed with any National Cancer Institute (NCI)-reportable cancers, including ductal carcinoma in situ (DCIS) and/or in situ breast cancer
  • COHORT B: Must have had an encounter within past twelve months
  • COHORT B: Exclude Cohort A
  • COHORT C: Creation of secure Hop app account
  • COHORT C: Consent to this project, either hard or electronic signature
  • COHORT C: Consent to the HOP repository, either hard or electronic signature
  • COHORT C: Choosing to submit a DNA sample
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27,500 participants (estimated)

Study arms

  • Other
    Screening (genetic testing)

    Patients undergo collection of saliva samples for genetic testing. If genetic test is positive, patients receive genetic counseling.

    Procedure: Biospecimen Collection · Other: Genetic Counseling · Other: Genetic Testing · Other: Survey Administration

Interventions

  • ProcedureBiospecimen Collection

    Undergo collection of saliva sample

    Also known as: Biological Sample Collection

  • OtherGenetic Counseling

    Receive genetic counseling if testing results are positive

  • OtherGenetic Testing

    Undergo genetic testing

    Also known as: genetic analysis, Genetic Examination, Genetic Test

  • OtherSurvey Administration

    Complete a survey

06

What researchers measure

Primary outcomes

  1. Effectiveness and sustainability of heritable cancer syndrome testing in the two novel testing populations

    Determine the costs and effectiveness, specifically Quality Adjusted Life Years (QALYs) associated with genetic screening models based on Cohorts B and C to estimate incremental cost-effectiveness ratio (ICER) and show that the costs per QALY are below the acceptable cost effectiveness threshold.

    Time frame: Up to 5 years

  2. Adherence to standard of care for hereditary breast and ovarian cancer (HBOC) and Lynch syndromes

    For Lynch syndrome we identify compliance as colonoscopy in past two years and bilateral salpingo-oophorectomy (BSO ) after child-bearing age. For HBOC, compliance is defined as breast imaging in past year or risk reducing surgery at any point in women.

    Time frame: Up to 5 years

  3. Merged risk reduction strategies of bilateral salpingo-oophorectomy (BSO) or bilateral mastectomy and imaging

    The merged risk reduction strategies of BSO or bilateral mastectomy and the imaging are treated as evidence of risk reducing behavior.

    Time frame: Up to 5 years

  4. Cascade screening rate among Lynch or HBOC positive carriers

    Will conduct negative binomial regression model and non-inferiority will be determined by rate ratio and its 95% confidence interval (CI).

    Time frame: Up to 5 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data and samples collected under this protocol will be stored indefinitely in this study's repository for future research use. Participants must agree to future research use of their samples/data to participate in HOP. Data/samples from participants who identify as American Indian/Alaska Native will be flagged within the HOP database so they can be excluded from data/sample releases for research purposes. HOP has created a Data Access Committee (DAC) to review all requests for HOP data/samples. The DAC will review requests for feasibility and scientific merit before any data/samples are released. OHSU investigators wishing to receive data from this study will sign a data release agreement documenting they will: Meet all IRB requirements (IRB approval, exemption or nonhuman subjects research determination), as appropriate. Use data only for the research described in their data request and/or IRB application/ protocol and obtain additional IRB approval if secondary studies are

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Dec 2027, 93 months after the start.

Of 23 interventional studies with no phase under Hereditary Breast and Ovarian Cancer Syndrome, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31. This study's planned 93 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2020
First posted
Jul 31, 2020
StartActual
Mar 9, 2020
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04494945
Responsible party
Jackie Shannon (Principal Investigator, OHSU Knight Cancer Institute) — Principal investigator
First posted
Jul 31, 2020
Start date
Mar 9, 2020
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Jackilen Shannon, Ph.D.
principal investigator · OHSU Knight Cancer Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion